ClinicalTrials.gg
CompletedNCT06473662Updated Feb 6, 2025Results posted

Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects

A Phase 2 interventional study of Oral insulin in Type 2 Diabetes Treated With Insulin, sponsored by Roger New. Completed at 1 site in United Kingdom. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Roger New · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 7 months after the study started (first participant enrolled Oct 2018, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
15th of 54
153 · median 60
Started
2018
with 1 other
Phase 2
11 of 54
none open now
Registered
51st of 54
by date

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 51st registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.

03

Conditions studied

  • Type 2 Diabetes Treated With Insulin
04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 35 to 60 years (both inclusive)
  2. Type 2 diabetes mellitus diagnosed \< 2 years prior to enrolment
  3. level ≥ 7% and ≤ 9.5%
  4. On stable oral monotherapy with metformin hydrochloride (1000 mg to 2500 mg/day) and regular diet and exercise regimen at least 12 weeks prior to enrolment
  5. between 18 to 30 kg/m2
  6. Ability to perform capillary blood glucose measurements
  7. Willing to provide informed and written consent for the clinical trial
  8. Able to comply with all requirements of clinical trial protocol

Exclusion criteria

Exclusion Criteria:

  1. Subject with history or evidence of to insulin or metformin hydrochloride or its
  2. Suffering from type 1 diabetes mellitus
  3. Received treatment with sulphonylureas or alpha-glucosidase inhibitors, Glucagonlike peptide-1 (GLP-1) receptor agonists or Sodium-glucose co-transporter 2 (SGLT2) inhibitors or meglitinides or pramlintide or thiazolidinediones within 3 months prior to enrolment
  4. Previously treated with insulin within 3 months prior to enrolment
  5. History of episodes of hypoglycaemia during 3 months prior to enrolment.
  6. Reduced awareness of hypoglycaemia or inability to identify and tackle hypoglycaemic episodes
  7. History of substantial weight loss defined as 5% decrease in body weight within the last 6 months
  8. Medical history of unstable angina within 1 year prior to enrolment
  9. History of tobacco or nicotine more than two packs/day within 3 months prior to enrolment
  10. Is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within 1 year prior to enrolment) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking).
  11. History of gastrointestinal disorders which may potentially interfere with absorption of the product
  12. Treatment with systemic or with inhalational corticosteroids (Beclomethasone or budesonide) within the 3 months prior to enrolment
  13. Likelihood of requiring treatment during the study period with prohibited medications mentioned (as defined in this clinical trial protocol)
  14. Female subject who is pregnant, lactating or planning pregnancy during the trial
  15. Female subject of childbearing age who is not willing to use adequate method of during the study period
  16. of less than 6 months from screening
  17. Elective surgery or any other surgical procedure/s requiring general anaesthesia during the clinical trial
  18. Has participated in another research trial within 12 weeks prior to screening
  19. History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy

    1. Subject having any of the following laboratory results at screening
    2. Estimated (eGFR) \<45 mL/min/1.73 m2
    3. (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal
  20. Blood urea nitrogen (BUN) > 30 mg/dL
  21. Subject who has a positive serology for virus (HBV) or (HCV) or (HIV) infections at screening
  22. Subject who has undergone pancreatectomy or pancreas islet transplant or renal transplant
  23. Subject receiving or has received any immunomodulation medications within 1 year prior to enrolment
  24. Subject with history or evidence of diabetic complications (e.g. diabetic retinopathy, diabetic neuropathy, or diabetic nephropathy, etc.), cardiac disorders, or any other systemic complication due to diabetes, which in the opinion of the Investigator signifies subjects' ineligibility for the trial
  25. Has any concurrent disease or medical/surgical condition, which required treatment of more than 3 months and which in the opinion of the Investigator does not allow participation of the subject in this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    75iu

    Capsule containing 75iu recombinant human insulin administered two times per day

    Drug: Oral insulin

  • Experimental
    150iu

    Capsule containing 150iu recombinant human insulin administered two times per day

    Drug: Oral insulin

  • Experimental
    300iu

    Capsule containing 300iu recombinant human insulin administered two times per day

    Drug: Oral insulin

Interventions

  • Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in HbA1c Relative to Baseline at Start of Study

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Fasting Plasma Glucose

    Change in Fasting Plasma Glucose Relative to Baseline at Start of Study

    Time frame: 12 weeks

  2. Change in Post-Prandial Glucose

    Change in Post-Prandial Glucose Relative to Baseline at Start of study

    Time frame: 12 weeks

  3. Changes in Triglycerides

    Change in Triglycerides Relative to Baseline at Start of Study

    Time frame: 12 weeks

07

Results

Posted Feb 6, 2025

Participant flow

204 patients were assessed for eligibility - 51 did not meet the inclusion criteria. Recruitment was conducted in hospital clinics and commenced one month before the start of study in October 2018

Participant flow — Overall Study
Milestone75iu150iu300iu
Started515052
Completed332938
Not completed182114
Withdrew: Withdrawal by subject165
Withdrew: Uncontrolled hyperglycaemia122
Withdrew: Starting hba1c below 7%011
Withdrew: No data from central lab (protocol violation)1494
Withdrew: Did not take medication232

Outcome measures

PrimaryChange in HbA1c

Change in HbA1c Relative to Baseline at Start of Study

Time frame:
12 weeks
Reported as:
Mean · % of glycated haemoglobin
Change in HbA1c
% of glycated haemoglobin75iu150iu300iu
Change in HbA1c-0.20 ± 1.06-0.53 ± 1.04-0.31 ± 1.04
Statistical analysis
  • 150iu · t-test, 2 sided · p = 0.0039 · Mean difference (final values): -0.53
SecondaryChange in Fasting Plasma Glucose

Change in Fasting Plasma Glucose Relative to Baseline at Start of Study

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Change in Fasting Plasma Glucose
mg/dL75iu150iu300iu
Change in Fasting Plasma Glucose-14.8 ± 53.6-18.8 ± 39.8-2.7 ± 60.09
Statistical analysis
  • 150iu · t-test, 2 sided · p = 0.0166 · Mean difference (final values): -18.8
SecondaryChange in Post-Prandial Glucose

Change in Post-Prandial Glucose Relative to Baseline at Start of study

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Change in Post-Prandial Glucose
mg/dL75iu150iu300iu
Change in Post-Prandial Glucose-17.4 ± 83.74-21.0 ± 86.4-31.0 ± 97.7
SecondaryChanges in Triglycerides

Change in Triglycerides Relative to Baseline at Start of Study

Time frame:
12 weeks
Reported as:
Least squares mean · mg/dL
Changes in Triglycerides
mg/dL75iu150iu300iu
Changes in Triglycerides-7.06 ± 10.23-22.13 ± 11.0220.56 ± 9.61
Statistical analysis
  • 150iu · ANCOVA · p = 0.0474 · Mean difference (final values): -22.13

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
75iu0/33 (0%)0/33 (0%)0/33 (0%)
150iu0/29 (0%)0/29 (0%)0/29 (0%)
300iu0/38 (0%)0/38 (0%)0/38 (0%)

Baseline characteristics

Baseline Analysis Population is the number of patients who completed the study according to protocol

Age, Categorical
Age, Categorical(Participants)75iu150iu300iuTotal
<=18 years0000
Between 18 and 65 years332938100
>=65 years0000
Age, Customized
Age, Customized(years)75iu150iu300iuTotal
Mean48.8 ± 6.446.6 ± 6.349.7 ± 7.148.5 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)75iu150iu300iuTotal
Female20161652
Male13132248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)75iu150iu300iuTotal
Hispanic or Latino0000
Not Hispanic or Latino332938100
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)75iu150iu300iuTotal
India332938100
HbA1c (%)
HbA1c (%)(%)75iu150iu300iuTotal
Mean8.27 ± 0.668.13 ± 0.657.93 ± 0.618.1 ± 0.65
Body weight (kg)
Body weight (kg)(kg)75iu150iu300iuTotal
Mean63.9 ± 8.366.1 ± 8.866.9 ± 12.565.7 ± 10.2
BMI (kg/m2)
BMI (kg/m2)(kg/m2)75iu150iu300iuTotal
Mean25.6 ± 3.025.8 ± 2.725.7 ± 2.925.7 ± 2.8

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Diabetology
    London, NW1 0NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2020, 20 months.

Results were first posted in Feb 2025, 4 years 6 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 20 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jun 25, 2024
StartActual
Oct 22, 2018
Primary completionActual
Jul 11, 2020
CompletionActual
Jul 11, 2020
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06473662
Lead sponsor
Roger New
Responsible party
Roger New (Chief Scientific Officer, Diabetology Limited) — Sponsor-investigator
First posted
Jun 25, 2024
Start date
Oct 22, 2018
Primary completion
Jul 11, 2020
Completion
Jul 11, 2020
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion